TSTL

Tristel PLC

Health Care First-pass screen £188m

460/1000 Overall fit

AI beneficiary 35% 25

Operating leverage 25% 72

Valuation 25% 35

Downside protection 15% 68

First-pass take

Tristel is a profitable, cash-generative infection-prevention company with strong operating leverage (11% revenue growth driving 23% profit growth) and disciplined capital allocation. However, it has zero AI exposure or beneficiary characteristics. Growth is slowing (16% CAGR to 11% FY2025) and no valuation data in filing limits assessment.

Flags

no-ai-exposureno-valuation-datacustomer-concentrationmature-marketdefensivefx-risk